Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 20/20 | 0.63 |
| ▸ | KCNJ11 | Q14654 | 20/20 | 0.63 |
| ▸ | ABCC8 | Q09428 | 14/20 | 0.63 |
| ▸ | KCNJ8 | Q15842 | 14/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4255043 | 1.00 | ABCC9 (0.63) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL5073127 | 0.93 | ABCC9 (0.58) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7843620 | 0.92 | ABCC9 (0.57) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7099014 | 0.89 | ABCC9 (0.66) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7098949 | 0.89 | ABCC9 (0.63) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7148311 | 0.86 | ABCC9 (0.76) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7149143 | 0.86 | ABCC9 (0.76) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7147032 | 0.86 | ABCC9 (0.76) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7145347 | 0.86 | ABCC9 (0.76) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7149196 | 0.86 | ABCC9 (0.76) | ABCC9KCNJ11ABCC8KCNJ8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642222-B2 | Useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions | ABBOTT LABORATORIES | 2003-11-04 | — | — | US | claimed |
| US-20030055035-A1 | Pyrano piperidino and thiopyrano compounds and methods of use | ABBOTT LABORATORIES | 2003-03-20 | — | — | US | claimed |
| EP-1278747-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | Abbott Laboratories (US) | 2003-01-29 | — | — | EP | claimed |
| WO-2001083484-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2001-11-08 | — | — | WO | claimed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-6642222-B2 | Useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions | ABBOTT LABORATORIES | 2003-11-04 | — | — | US | disclosed |
| US-6632418-B2 | Therapy for asthma, sexual disorders, hypotensive agents, analgesics | ABBOTT LABORATORIES | 2003-10-14 | — | — | US | disclosed |
| US-20030065182-A1 | Novel radioligands and their use for identifying potassium channel modulators | ABBOTT LABORATORIES | 2003-04-03 | — | — | US | disclosed |
| US-20030055035-A1 | Pyrano piperidino and thiopyrano compounds and methods of use | ABBOTT LABORATORIES | 2003-03-20 | — | — | US | disclosed |
| EP-1278747-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | Abbott Laboratories (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001083484-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055035-A1 | Pyrano piperidino and thiopyrano compounds and methods of use | KCNJ3, KCNJ6, KCNJ5 | ABCC9 632/4885KCNJ11 4/4885ABCC8 915/4885 |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | PYGB, PC, KCNN3 | ABCC9 384/4885KCNJ11 18/4885ABCC8 415/4885 |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | PC, LIPE, ATP5ME | ABCC9 482/4885KCNJ11 24/4885ABCC8 605/4885 |
| US-20030065182-A1 | Novel radioligands and their use for identifying potassium channel modulators | KCNN3, KCNN1, KCNN2 | ABCC9 512/4885KCNJ11 47/4885ABCC8 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.